Focusing On The Bigger Picture At The EMA
Top Agency Exec Talks Life Beyond Brexit And Coronavirus
Tony Humphreys of the European Medicines Agency explains the thinking behind the agency’s regulatory science strategy, why the PRIME scheme is to get a boost, and why the need to tackle health threats ranked so low in a stakeholder consultation.
You may also be interested in...
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.